Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A versus pembrolizumab first-line treatment for PD-L1-positive metastatic non-small cell lung cancer
CTR20211859Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vibostolimab + pembrolizumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jan 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211859.